Carlsmed (CARL) EBITDA (2024 - 2026)

Carlsmed has reported EBITDA for 3 years, with the latest figure at -$8.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 51.79% year-over-year to -$8.7 million; the trailing twelve-month figure through Mar 2026 stood at -$32.6 million (down 32.85% YoY), and the FY2025 full-year result was -$29.6 million, down 22.17% from the prior year.
• EBITDA for Q1 2026 stood at -$8.7 million, down from -$8.6 million in the prior quarter.
• The five-year high for EBITDA was -$4.7 million in Q4 2024, with the low at -$8.7 million in Q1 2026.
• Historically, EBITDA has averaged -$7.1 million across 3 years, with a median of -$7.3 million in 2024.
• The largest YoY upside for EBITDA was 7.79% in 2025 against a maximum downside of 82.48% in 2025.
• Carlsmed's EBITDA stood at -$4.7 million in 2024, then sank by 82.48% to -$8.6 million in 2025, then dropped by 0.96% to -$8.7 million in 2026.
• The last three EBITDA figures came in at -$8.7 million (Q1 2026), -$8.6 million (Q4 2025), and -$8.5 million (Q3 2025), per Business Quant data.